BEST UNLIMITED TURBO LONG CERTIFICATE - BRISTOL-MYERS SQUIBB | Market Closed - Euronext Paris 12:30:01 2024-06-07 pm EDT | ||
| 1.045 EUR | +0.97% |
|
| Current month | +3.86% | ||
| 1 month | -35.82% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 1.075 | +3.86% |
| 24-06-06 | 1.035 | -1.90% |
| 24-06-05 | 1.055 | -10.21% |
| 24-06-04 | 1.175 | -0.84% |
| 24-06-03 | 1.185 | +14.49% |
Real-time Euronext Paris
Last update June 07, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| 4N89S | |
| ISIN | DE000SU9QAY0 |
| Date issued | 2024-02-21 |
| Strike | 35.7 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 2.83 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.655 € |
|---|---|
| Lowest since issue | 0.845 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.48
USD
Average target price
53.19
USD
Spread / Average Target
+28.24%
- Stock Market
- Certificates
- 4N89S Certificat
